CEO, BlueSphere Bio
David brings extensive clinical development, research, and regulatory experience, spanning more than 20 years in large pharma and biotechnology companies across multiple therapeutic areas including hepatology, immuno-oncology, and rare diseases.
David was most recently Chief Operating Officer and Executive Medical Officer at Eiger Biopharma where he was responsible for the strategy and execution of late stage clinical development programs including chronic hepatitis D, progeria, and post-bariatric hypoglycemia. He still serves on the board of directors of Eiger. He served previously as Executive Vice President and Chief Medical Officer of Achillion Pharmaceuticals Inc. where he was instrumental in securing a partnership between Achillion and Johnson & Johnson, which resulted in a $225 million equity investment. From 2005 to 2013, David was Chief Medical Officer and subsequently head of all R&D and Regulatory Affairs for the immune oncology company GlobeImmune. Before that, he served as Medical Lead at Bristol-Myers Squibb. And prior to that, he was Clinical Director in the Department of Hepatology & Gastroenterology at Schering Plough.
David completed his residency training in pediatrics at New York Hospital, Cornell Medical Center, and is board certified in Pediatrics. He received a PhD in Biochemistry from Rutgers University, an MD from the University of Medicine and Dentistry of New Jersey, and an MBA from Quinnipiac University. He earned a BA in Biochemistry from Rutgers University.